What is the benefit of adding pevonedistat to azacitidine in patients with high-risk MDS or AML?

During the American Society of Clinical Oncology (ASCO) Annual Meeting, the MDS Hub was delighted to speak to Lionel Ades, Saint-Louis Hospital, Paris, FR. We asked: what is the benefit of adding pevonedistat to azacitidine in patients with high-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)?

In this video, Lionel Ades describes the results of the phase II study that evaluated this combination in patients who had not previously received hypomethylating agents and were ineligible for stem cell transplant. He describes the event-free survival results of the 120 patients enrolled in the study as well as the overall survival and duration of response in the three patient populations: high-risk MDS, high-risk AML or low blast AML.